Long-term clinical outcomes of [
Publication/Presentation Date
1-1-2024
Abstract
The incidence of gastroenteropancreatic neuroendocrine tumors has been rising and these tumors are usually only diagnosed at a metastatic stage. Present first line treatments include somatostatin analogs, targeted therapies and peptide receptor radionuclide therapy. The Lutetium-177 [
Volume
14
First Page
1393317
Last Page
1393317
ISSN
2234-943X
Published In/Presented At
Iqbal, S., Zhuang, E., Raj, M., Bahary, N., & Monga, D. K. (2024). Long-term clinical outcomes of [177Lu]Lu-DOTATATE in patients with metastatic neuroendocrine tumors. Frontiers in oncology, 14, 1393317. https://doi.org/10.3389/fonc.2024.1393317
Disciplines
Medicine and Health Sciences
PubMedID
38817893
Department(s)
Fellows and Residents
Document Type
Article
COinS